期刊
JOURNAL OF PHARMACOLOGICAL SCIENCES
卷 120, 期 2, 页码 133-137出版社
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1254/jphs.12096SC
关键词
dopamine receptor; Parkinson's disease; pramipexole
资金
- Research Committee of CNS Degenerative Diseases
- Ministry of Health, Labour and Welfare of Japan
- GJTS
Randomized clinical trials have shown that pramipexole has an antidepressant effect in patients with Parkinson's disease. We investigated the comparative efficacy of pramipexole toward dopamine receptor D-2 and D-3 expression in rat brain. Groups of rats were treated subacutely with pramipexole (1 mg/kg), imipramine (10 mg/kg), or bromocriptine (5 mg/kg), with appropriate controls. Using real-time RT-PCR and immunoblotting, dopamine receptor D-2 and D-3 expression was up-regulated in the striatum following pramipexole treatment, while imipramine and bromocriptine had no significant effects. These findings support that pramipexole exerts additional therapeutic benefits such as decreasing depression by increasing dopamine receptor D-3 expression in the striatum.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据